Fig. 3From: CRISPR–Cas9 applications in T cells and adoptive T cell therapiesCAR-T cells therapy in solid cancer. Barriers that exist in solid tumors with CAR-T cell therapy and CRISPR–Cas9 applications in editing CAR include (1) suppressive cytokines and chemokines, (2) tumor-specific antigens, (3) ineffectiveness of CAR-T cells infiltration, and (4) nutrition competition between tumor cells and CAR-T cells and the suppressive metabolitesBack to article page